A new trading day began on November 20, 2023, with Dermata Therapeutics Inc (NASDAQ: DRMA) stock priced at $0.6699, up 19.20% from the previous day of trading. During the day, the shares moved up to $0.8344 and dropped to $0.6452 before settling in for the closing price of $0.70. DRMA’s price has ranged from $0.56 to $11.84 over the past 52 weeks.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Meanwhile, its annual earnings per share averaged 69.68%. With a float of $2.79 million, this company’s outstanding shares have now reached $3.19 million.
Let’s determine the extent of company efficiency that accounts for 8 employees.
Dermata Therapeutics Inc (DRMA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Dermata Therapeutics Inc is 12.49%, while institutional ownership is 4.29%.
Dermata Therapeutics Inc (DRMA) Recent Fiscal highlights
In its latest quarterly report, released on 9/29/2023, the company reported earnings of -$0.54 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 69.68% per share during the next fiscal year.
Dermata Therapeutics Inc (NASDAQ: DRMA) Trading Performance Indicators
Here are Dermata Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.61, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -2.35 in one year’s time.
Technical Analysis of Dermata Therapeutics Inc (DRMA)
Looking closely at Dermata Therapeutics Inc (NASDAQ: DRMA), its last 5-days average volume was 2.06 million, which is a jump from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 44.00%. Additionally, its Average True Range was 0.11.
During the past 100 days, Dermata Therapeutics Inc’s (DRMA) raw stochastic average was set at 22.59%, which indicates a significant decrease from 66.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 166.50% in the past 14 days, which was higher than the 89.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8508, while its 200-day Moving Average is $1.7705. However, in the short run, Dermata Therapeutics Inc’s stock first resistance to watch stands at $0.8975. Second resistance stands at $0.9605. The third major resistance level sits at $1.0867. If the price goes on to break the first support level at $0.7083, it is likely to go to the next support level at $0.5821. Now, if the price goes above the second support level, the third support stands at $0.5191.
Dermata Therapeutics Inc (NASDAQ: DRMA) Key Stats
With a market capitalization of 2.66 million, the company has a total of 3,189K Shares Outstanding. Currently, annual sales are 0 K while annual income is -9,610 K. The company’s previous quarter sales were 0 K while its latest quarter income was -1,720 K.